Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595864 | 0.87 | RIPK1 (0.53) | NR1H2NR1H3RXRARIPK1GPR119 | |
| SCHEMBL8140446 | 0.86 | PARP1 (0.43) | NR1H2NR1H3PARP1TACR1 | |
| SCHEMBL22285173 | 0.86 | NR1H2 (0.49) | NR1H2NR1H3RXRARIPK1PARP1 | |
| SCHEMBL4325057 | 0.86 | NR1H2 (0.49) | NR1H2NR1H3RXRARIPK1PARP1 | |
| SCHEMBL874416 | 0.86 | NR1H2 (0.49) | NR1H2NR1H3RXRARIPK1PARP1 | |
| SCHEMBL3201139 | 0.84 | NR1H2 (0.44) | NR1H2NR1H3RXRARIPK1PARP1 | |
| SCHEMBL30910360 | 0.84 | TACR1 (0.39) | NR1H2NR1H3RIPK1PARP1TACR1 | |
| SCHEMBL21198773 | 0.83 | RIPK1 (0.53) | NR1H2NR1H3RIPK1GPR119 | |
| SCHEMBL21207072 | 0.83 | RIPK1 (0.53) | NR1H2NR1H3RIPK1GPR119 | |
| SCHEMBL4718386 | 0.83 | RIPK1 (0.53) | NR1H2NR1H3RIPK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| CN-102459258-A | Preparation and use of 1,2, 4-triazolo [1,5a ] pyridine derivatives | CEPHALON INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2438066-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES | Cephalon, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | JAK2, JAK1, JAK3 | NR1H2 2592/4885NR1H3 2699/4885RXRA 615/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | NR1H2 2009/4885NR1H3 1896/4885RXRA 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.